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Available online 5 February 2018Epidermal growth factor receptor (EGFR)-mutation-positive non-small cell lung cancer (NSCLC) is incurable, de-
spite high rates of response to EGFR tyrosine kinase inhibitors (TKIs). We investigated receptor tyrosine kinases
(RTKs), Src family kinases and focal adhesion kinase (FAK) as genetic modifiers of innate resistance in EGFR-
mutation-positive NSCLC. We performed gene expression analysis in two cohorts (Cohort 1 and Cohort 2) of
EGFR-mutation-positive NSCLC patients treated with EGFR TKI. We evaluated the efficacy of gefitinib or
osimertinib with the Src/FAK/Janus kinase 2 (JAK2) inhibitor, TPX0005 in vitro and in vivo. In Cohort 1, CUB
domain-containing protein-1 (CDCP1) was an independent negative prognostic factor for progression-free sur-
vival (hazard ratio of 1.79, p = 0.0407) and overall survival (hazard ratio of 2.23, p = 0.0192). A two-gene
model based on AXL and CDCP1 expression was strongly associated with the clinical outcome to EGFR TKIs, in
both cohorts of patients. Our preclinical experiments revealed that several RTKs and non-RTKs, were up-
regulated at baseline or after treatmentwith gefitinib or osimertinib. TPX-0005 plus EGFR TKI suppressed expres-
sion and activation of RTKs and downstream signaling intermediates. Co-expression of CDCP1 and AXL is often
observed in EGFR-mutation-positive tumors, limiting the efficacy of EGFR TKIs. Co-treatment with EGFR TKI
and TPX-0005 warrants testing.
© 2018 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Table 1
Patient characteristics in Cohort 1 and Cohort 2.
Clinical characteristics Cohort 1
(no = 64)
Cohort 2
(no = 53)
p Value test
Sex—no. (%)
Male 22 (34.4) 13 (24.5) Chi-Square:
0.2469Female 42 (65.6) 40 (75.5)
Age—yr
Median 67 63 Wilcoxon:
0.0494Range 35–89 26–87
ECOGa performance status —
no. (%)
0 15 (23.4) 10 (18.9) Fisher: 0.2204
1 49 (76.6) 43 (81.1)
Smoking status — no. (%)
Never smoked 42 (65.6) 42 (79.2) Fisher: b0.0001
Former smoker 17 (26.6) 1 (1.9)
Current smoker 5 (7.8) 0 (0.0)
Unknown 0 (0.0) 10 (18.9)
Disease stage — no. (%)
IIIB 12 (18.7) 0 (0.0)
IV 52 (81.3) 53 (100.0)
Brain metastasis — no. (%)
No 43 (67.2) 26 (49.1) Chi-Square:
0.6585Yes 21 (32.8) 27 (50.9)
Bone metastasis— no. (%)
No 40 (62.5) 31 (58.5) Chi-Square:
0.0472Yes 24 (37.5) 22 (41.5)
Type of EGFR mutation— no.
(%)
Exon 19 deletion 44 (68.8) 26 (49.1) Fisher: 0.0551
Leu858Arg 18 (28.1) 21 (39.6)
Otherb 2 (3.1) 6 (11.3)
Type of EGFR TKI— no. (%)
Erlotinib 37 (57.8) 46 (86.8)
Gefitinib 25 (39.1) 7 (13.2)
Afatinib 2 (3.1) 0 (0.0)
Progression-free survival
Median—mo (CI 95%) 14.1
(8.8–16.3)
13.0
(10.7–17.8)
Overall survival
Median—mo (CI 95%) 26.7
(17.9–37.1)
27.1
(22.8–29.9)
Best response— no. (%)
Complete response 3 (4.7) 12 (22.6)
Partial response 39 (60.1) 20 (37.7)
Stable disease 16 (25.8) 18 (34.0)
Progressive disease 6 (9.4) 3 (5.7)
a ECOG, Eastern Cooperative Oncology Group.
b Other, Cohort 1 Leu861Glu, Gly719X; Cohort 2 L861Q (no= 2), exon 20 insertion
(no = 3), S768I (no = 1); no, number; mo, months.
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Epidermal growth factor receptor (EGFR) gene mutations were
identified following the sequencing of 47 out of 58 receptor tyrosine
kinase (RTKs) in tumors of non-small cell lung cancer (NSCLC) pa-
tients (Paez et al., 2004). EGFR mutations, mostly small in-frame
exon 19 deletions and amino acid substitutions within exon 21, like
Leu858Arg, are sensitive to EGFR tyrosine kinase inhibitors (TKIs)
gefitinib (Paez et al., 2004; Lynch et al., 2004) and erlotinib (Rosell
et al., 2009). Despite the higher response rate and longer progres-
sion-free survival, there is no survival benefit with erlotinib in pa-
tients with EGFR mutations (Tsao et al., 2005). EGFR-mutation-
positive lung cancer cells undergo apoptosis following EGFR knock-
down, or pharmacological inhibition of AKT and signal transducer
and activator of transcription 3 (STAT3), while they are relatively re-
sistant when treated with chemotherapy (Sordella et al., 2004). De-
spite these observations, studies have focused on comparing EGFR
TKIs versus chemotherapy for EGFR-mutation-positive NSCLC.
Phase 3 trials have compared gefitinib or erlotinib with chemother-
apy, confirming the significantly longer progression-free survival
with EGFR TKIs (Mok et al., 2009; Rosell et al., 2012). The second-
generation irreversible EGFR TKIs, afatinib and dacomitinib, have
been found to be superior to gefitinib (Park et al., 2016; Wu et al.,
2017). Osimertinib, a third-generation irreversible EGFR-TKI that in-
hibits also the EGFR Thr790Met point resistant mutation, yields sig-
nificantly longer progression-free survival in comparison with
standard EGFR TKIs as first-line treatment (Soria et al., 2018). Com-
plete responses are uncommon, regardless of the EGFR TKI, and pa-
tients ultimately succumb to the disease.
EGFR-mutation-positive NSCLC expressesmultiple RTKs and/or non-
RTKs, mainly focal adhesion kinase (FAK), encoded by the protein tyro-
sine kinase 2 (PTK2) gene and Src family kinases (SFK) (Rikova et al.,
2007). EGFR inhibition increases the phosphorylation of the co-
existing non-targeted RTKs, maintaining redundant downstream sig-
naling (Stommel et al., 2007). Inter-receptor crosstalk of MET, integrin
beta-4, erythropoietin-producing hepatocellular (EphA2), CUB
domain-containing protein-1 (CDCP1) and AXL was described in
EGFR-mutation-positive NSCLC (Gusenbauer et al., 2013). Numerous
co-expressed RTKs and non-RTKs were observed in the EGFR-
mutation-positive PC9 and PC9 gefitinib-resistant cells. The combina-
tion of afatinib or osimertinib with the Src inhibitor dasatinib caused
tumor regression in EGFR-mutation-positive cells (Yoshida et al., 2014;
Ichihara et al., 2017). SFK and FAK induce resistance to afatinib, erlotinib
and osimertinib (Murakami et al., 2017). Moreover, RTK-driven cancers
depend on Src-homology 2 domain-containing phosphatase 2 (SHP2),
encoded by the protein tyrosine phosphatase, non-receptor type 11
(PTPN11) gene and SFKs for survival (Sausgruber et al., 2015). We re-
ported that either gefitinib or osimertinib activates STAT3 and Src-
YES-associated protein 1 (YAP1) in EGFR-mutation-positive lung cancer
cells (Chaib et al., 2017). STAT3, when activated, translocates into the
nucleus and promotes gene transcription (Gao et al., 2007). Combined
EGFR, STAT3 and Src inhibition abrogated tumor growth more effi-
ciently than single EGFR inhibition both in culture and in vivo (Chaib
et al., 2017). AXL was identified as a downstream target of YAP1 in he-
patocellular carcinoma (Xu et al., 2011).We noted that in EGFR TKI re-
sistant cells, due to either EGFR Thr790Met point resistant mutation
or AXL overexpression (Zhang et al., 2012), afatinib combined with a
STAT3 blocker induced tumor growth regression (Codony-Servat
et al., 2017).
Here, we show that the co-activation of RTKs and non-RTKs is a
common trait in treatment-naïve EGFR-mutation-positive NSCLC
cells and patients, with AXL and CDCP1 being commonly over-
expressed. The combination of gefitinib or osimertinib with the
Src/FAK/Janus kinase 2 (JAK2) inhibitor TPX-0005 (Zhai et al.,
2016) abrogates STAT3, YAP1 and SFKs activation and down-
regulates AXL and CDCP1 expression.2. Methods
2.1. Study Oversight and Sample Collection
Clinical data were assessed in accordance with the protocol ap-
proved by the institutional review board of Germans Trias i Pujol Hospi-
tal, Badalona and de-identified for patient confidentiality. The first and
last authorwrote thefirst version of themanuscript. All authors contrib-
uted to subsequent drafts and vouch for the accuracy of the data. We
studied pre-treatment tumors from 2 cohorts of EGFR-mutation-
positive NSCLC patients. Cohort 1 was from hospitals in Spain, France,
Italy and Colombia (Chaib et al., 2017). Cohort 2 was from the Clinica
del country in Bogota, Colombia. The baseline characteristics of the pa-
tients are found in Table 1.
2.2. Chemicals and Reagents
Gefitinib was purchased from Tocris Bioscience Company (Bristol,
UK). Afatinib, dacomitinib, osimertinib and dasatinib were purchased
from Selleck Chemicals (Houston, TX, U.S). TP Therapeutics Inc. (San
Diego, CA, U.S) has developed the Src/FAK/JAK2 inhibitor TPX-0005
114 N. Karachaliou et al. / EBioMedicine 29 (2018) 112–127(Table 2). The compoundwas kindly provided to us by TP Therapeutics,
Inc. under a material transfer agreement (MTA). TPX-0005 is a
multikinase inhibitor (Zhai et al., 2016; Cui et al., 2017) with a rigid
three-dimensional macrocyclic structure, currently in a phase I/II clini-
cal trial (NCT03093116). Drugs were prepared in dimethyl sulfoxide
(DMSO) at a concentration of 10-100mmol/l stock solutions and stored
at−20 °C. Further dilutions were made in culture medium to final con-
centration before use. Primary antibodies and secondary antibodies
used are in Supplementary Table 1.
2.3. Cell Viability Assay
PC9 (exon 19deletion) cells were provided by F. Hoffmann-La Roche
Ltd. 11–18 (Leu858Arg) cells were provided by Dr. Mayumi Ono. H1975
(Leu858Arg and Thr790Met), HCC4006 (exon 19 deletion) and HCC827
(exon 19 deletion) cells were purchased from the American Type Cul-
ture Collection (ATCC). Cells were seeded on 96-well plates at the
following densities: 2 × 103, 3 × 103 and 4 × 103 cells/well and incu-
bated for 24 h, as previously described (Chaib et al., 2017). Cells were
treated with serial dilutions of the drugs administrated at indicated
doses. After 72 h of incubation, 0.5 mg/ml of MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent
(Sigma-Aldrich, St. Louis, MO, U.S) was added to the medium in the
wells for 2 h at 37 °C and formazan crystals in viable cells were solubi-
lized with 100 μl DMSO and spectrophotometrically quantified using a
microplate reader (Varioskan Flash; Thermo Fisher Scientific,Waltham,
MA, U.S) at 550 nm of absorbance. Fractional survival was then calcu-
lated as percentage to control cells. Data of combined drug effects
were subsequently analyzed by the Chou and Talalay method (Chou,
2010; Narayan et al., 2017). Combination Index (CoI) values b1, =1
and N1 indicated synergism, additive effect and antagonism,
respectively.
2.4. Colony Formation Assay
Cells were plated in six-well plates at 1000 cells/well in Roswell Park
Memorial Institute (RPMI) 1640 Medium and 10% fetal bovine serum
(FBS), as previously described (Chaib et al., 2017). The cells were cul-
tured for 24 h and the media were then replaced with RPMI, 1% FBS
with or without inhibitors. After 72 h the media were removed and re-
placed with fresh media without inhibitors for a total of 10 days. At the
end of the experiment, the media were removed and the cells were
washed with phosphate-buffered saline (PBS). The colonies were fixed
and stained simultaneously with 0.5% crystal violet in 10% of ethanol
for 15min. The stain was aspirated and thewells were washedwith de-
ionized water until the background was clear. The wells were then
photographed. As a semiquantitative measurement, the crystal violetTable 2
In vitro kinase activity of TPX-0005.
Target IC50 (nM) at 10
μM ATP
Target IC50 (nM) at 10
μM ATP
Target IC50 (nM) at 10
μM ATP
TRKB 0.05 SNARK 13.0 JAK3 50
ROS1 0.07 HCK 16.4 EPHA8 50.2
TRKC 0.1 IRR 18.1 IGFR 111
TRKA 0.83 LCK 18.6 PLK4 126
ALK 1.04 JAK1 19 AXL 149
JAK2 1.04 TYK2 21.6 MARK3 512
FYN 1.05 LTK 21.8
LYN 1.66 DDR2 23
YES 2.15 BTK 23.7
FGR 3.05 TNK2 24.1
TXK 3.17 EPHA1 25.0
ARK5 4.46 BLK 32.3
SRC 5.3 GRK7 35.2
DDR1 5.7 PYK2 39.9
FAK 6.96 RET 47.1was extracted from the colonies with Triton X-100 0.5% solution over-
night and the absorbance was measured at 570 nm.2.5. Western Blotting
Cellswerewashedwith cold PBS and re-suspended in ice-cold radio-
immunoprecipitation assay buffer (50 mM Tris- hydrochloric acid in
pH 7.4, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dode-
cyl sulfate [SDS], 150 mM sodium chloride, 1 mM ethylenediaminetet-
raacetic acid, 1 mM sodium vanadate and 50 mM sodium fluoride)
containing protease inhibitor mixture. Following cell lysis by sonication
and centrifugation at 14000 rpm (revolutions per minute of rotor) for
15 min at 4 °C, the resulting supernatant was collected as the total cell
lysate. Briefly, the lysates containing 30 μg proteins were electropho-
resed on 10% SDS-polyacrylamide gel electrophoresis (Life Technolo-
gies, Carlsbad, CA, U.S) and transferred to polyvinylidene difluoride
membranes (Bio-Rad laboratories Inc., Hercules, CA, U.S). Membranes
were blocked in Odyssey blocking buffer (Li-Cor Biosciences, Lincoln,
NE, U.S). All target proteins were immunoblotted with appropriate pri-
mary and either IRDye-conjugated or horseradish peroxidase (HPR)-
conjugated secondary antibodies. Fluorescent bands (IRDye-conju-
gated) were detected with Odyssey CLx Imager (Li-Cor Biosciences),
whereas chemiluminescent (HRP-conjugated) were detected in a
ChemiDoc MP Imaging System (Bio-Rad laboratories Inc.). β-actin was
used as an internal control to confirm equal gel loading.2.6. Phospho-receptor Tyrosine Kinase and Phosphokinase Arrays
For phosphoproteomics analysis, 0.7 × 106 cells were seeded in T25
flasks (Starstedt, Newton, U.S). The next day, PC9 cells were treated
with 50 nM gefitinib, 1 μM TPX-0005 or a combination of both. H1975
cells were treated with 10 nM osimertinib, 1 μM TPX-0005 or a combi-
nation of both. Untreated cells received an equivalent dose of vehicle
(DMSO). After 24 h cells were lysed and hybridized in Proteome Profiler
Human Phospho-RTK (ARY001B) or Phospho-Kinase (ARY003B) array
membranes (R&D Systems Inc., Minneapolis, MN, U.S). Lysis, hybridiza-
tion and development of the membranes were performed following
manufacturer's instructions. Images were taken in a Chemidoc MP Im-
aging System and processed using Image Lab software (both from Bio-
Rad laboratories Inc.). Spot intensity was determined using Quantity
One software (Bio-Rad laboratories Inc.). Spot intensities were normal-
ized to control (untreated) levels and a heatmap was generated using
Microsoft Excel. Thewhole experimentwas repeated twicewith similar
results.2.7. Small Interfering RNA Transfections
Flexi-tube small interfering RNAs (siRNA) (Qiagen Inc., Valencia, CA,
U.S) were transfected using Lipofectamine 3000 (Thermo Fisher Scien-
tific) following manufacturer instructions. The same transfection mix
was used to transfect cells for viability assays and for western blotting
to check knockdown. In parallel, PC9 and H1975 cells were transfected
with Alexa Fluor 488-labeled Allstars siRNA (Qiagen Inc.) to verify
transfection efficiency, which was higher than 95% for both cell lines.
For Western blot, cells were lysed 48 h after transfection. For viability
assays, cells were treated the day after transfection and drugs were
maintained for 72h before theMTT assay. The experimentwas repeated
three times with different set of siRNAs. siRNAs usedwere: SI03650325
for non-targeting control; SI02662898, SI02662338 and SI00048377 for
STAT3; SI02664151, SI02223928 and SI02223921 for Src, SI02662954,
SI04438651 and SI04438644 for YAP1, SI02223942, SI02223935 and
SI00302218 for YES and SI00605577, SI00605570 and SI04713513 for
LYN.
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For immunocytochemistry, 2 × 104 cells were seeded on coverslips
placed on 24-well plates and grown overnight. The next day cells
were treated with IC50 values of the indicated drugs. 24 h later, cover-
slips were washed with PBS, fixed with 4% paraformaldehyde (PFA)
for 15 min and treated with cold methanol. After a wash in immunocy-
tochemistry wash buffer (PBS 1×, 0.1% Troton-X-100, 0.05% Sodium
Azide, 0.5% bovine serum albumine), coverslips were blocked in immu-
nocytochemistry wash buffer containing 10% FBS for 20 min at room
temperature and incubated overnight with primary antibodies against
the indicated epitopes at 4 °C. After three wash steps, Alexa Fluor 488-
coupled secondary antibodies (Thermo Fisher Scientific) were incu-
bated at room temperature for 2 h. Coverslips were washed three
times with immunocytochemistry wash buffer before 4′,6-diamidino-
2-phenylindole (DAPI) counterstain and washed once more with H2O
before being mounted with Vectashield (Vector Laboratories, Burlin-
game, CA, U.S) on glass slides. For imaging flow cytometry analysis, 1
× 106 cells were seeded on 21 cm2 cell-repellent plates. The next day,
cells were treatedwith the indicated drugs with concentrations equiva-
lent to their IC50 values for 24 h, stained with the Live/Dead Fixable Far
RedDead Cell Stain Kit (Thermo Fisher Scientific) to label dead cells and
immunostained as indicated above. Aminimum of 105 events were col-
lected at 4000× in an ImagestreamX imaging flow cytometer (EMD
Millipore, Billerica, MA, U.S) using Inspire software (EMD Millipore).
Data was compensated and processed to render focused images of sin-
gle cells and intensity and localization of the Alexa-488 signal was ana-
lyzed using IDEAS software (EMD Millipore).
2.9. Immunohistochemistry
All the immunohistochemistry experiments were performed on a
Ventana Benchmark Ultra automated staining (Ventana Medical Sys-
tems Inc., Tuscon, AZ, U.S). Immunohistochemistry of the tumor
samples was performed on 4 μm sections. The settings included pre-
treatment with cell conditioner 1 (CC1) buffer for 56 min, incubation
with a phosphorylated STAT3 (1:200) antibody for 40 min, and pre-
treatmentwith CC1 buffer for 76min, incubationwith a phosphorylated
YAP1 (1:200) antibody for 28 min. The detection was performed with
3,3-diaminobenzidine (DAB) detection kit (Ventana Medical Systems
Inc.) according to the manufacturer's instructions. Slides were
counterstained with hematoxylin and mounted. The evaluation of
immunohistochemically labeled samples with these antibodies in-
cluded the percentage of positively stained tumor cells and their inten-
sity aswell as the staining localization (cytoplasmic, nuclear). The semi-
quantitative evaluation was performed using the H-score classification.
The percentage of negative (0), weakly stained (1+), moderately
stained (2+) and strongly stained (3+), tumor cells was estimated
and the H-score was calculated as follows: H-score = 1 × (% of 1+
staining) + 2 × (% of 2+ staining) + 3 × (% of 3+ staining).
2.10. Quantitative Real-time Polymerase Chain Reaction (RT-PCR) Analyses
Paraffin-embedded samples and slides were obtained by standard
procedures. If the tumor infiltration rate was b85%, the selected tumorFig. 1.Progression-free survival by the expression of biomarkers in 2 cohorts of EGFR-mutation p
30.2) for the 21 patients with low AXL and 14.1 months (95% CI, 5.4 to 15.8) for the 21 patients
was 20.2months (95%CI, 8.5 to 30.2) for the 24 patientswith low CDCP1 and 9.1months (95%C
C. Univariate analysis was performed in Cohort 1. The bars correspond to 95% confidence interv
risk groupwith amedianprogression-free survival of 10.3months (95%CI, 3.0 to 14.2) and comb
amedian progression-free survival of 23.4months (95%CI, 13.4 to 28.1); p=0.0079 (Cohort 1)
low AXL and 10.7 (95% CI, 8.0 to 13.0) for the 21 patients with high AXLmRNA expression; p=
22.0) for the 34 patients with low CDCP1 and 11.1 months (95% CI, 9.0 to 14.0) for the 19 patie
performed in Cohort 2. The bars correspond to 95% confidence intervals. H. Combined AXL and
progression-free survival of 10.7months (95% CI, 7.2 to 14.8) and combined AXL or CDCP1mRN
free survival of 15.0 months (95% CI, 11.1 to 19.5); p = 0.0192 (Cohort 2).area was captured by laser micro-dissection (Zeiss-Palm, Oberlensheim,
Germany); otherwise, manual macro-dissection was performed. RNA
was isolated from the tumor tissue specimens and the cell lines in accor-
dance with a proprietary procedure (European patent number
EP1945764-B1). Briefly, samples were lysed in a trischloride, ethylene-
diaminetetraacetic acid (EDTA), SDS and proteinase K containing buffer.
Then, RNA was extracted with phenol-chloroform-isoamyl alcohol,
followed by precipitation with isopropanol in the presence of glycogen
and sodium acetate. RNA was re-suspended in water and treated with
DNAse I to avoid DNA contamination. Complementary DNA (cDNA)
was synthesized using M-MLV (Moloney Murine Leukaemia Virus Re-
verse Transcriptase) retro-transcriptase enzyme. cDNA was added to
Taqman Universal Master Mix (Applied Biosystems, Carlsbad, CA, U.S)
in a 12.5 μl reaction with specific primers and probe for each gene. The
primer and probe sets were designed using Primer Express 3.0 Software
(Applied Biosystems) according to their Ref Seq (http://www.ncbi.nlm.
nih.gov/LocusLink). Gene-specific primers are provided in the Supple-
mentary material. Quantification of gene expression was performed
using the ABI Prism 7900HT Sequence Detection System (Applied
Biosystems) and was calculated according to the comparative Ct
method. Final results were determined as follows: 2-(ΔCt sample-ΔCt calibra-
tor), where ΔCt values of the calibrator and sample are determined by
subtracting the Ct value of the target gene from the value of the endog-
enous gene (β-actin). Commercial RNA controlswere used as calibrators
(Liver and Lung; Stratagene, La Jolla, CA, USA). In all quantitative exper-
iments, a sample was considered not evaluable when the standard devi-
ation of theCt valueswas N0.30 in two independent analyses. As a result,
the number of evaluable samples varied among the genes examined. All
analyses of the cell lines and samples in the 2 cohortswere carried out at
the ISO 15189-certified Pangaea Oncology laboratory located in the
Quiron Dexeus University Hospital (Barcelona, Spain).
2.11. Animal Experiments
Nu/Nu mice of four to five weeks were obtained from Nanjing Bio-
medical Research Institute of Nanjing University (Nanjing, Jiangsu,
China). All animals were maintained in a clean facility in Jiangsu Prov-
ince Academy of Traditional Chinese Medicine (Nanjing, Jiangsu,
China). Mice were kept in Individually Ventilated Cages (IVCs) (6 per
cage) with free access of food and water, at 20 °C and 50± 20% relative
humidity under a 12:12 h light:dark cycles and pathogen free condi-
tions. All procedures were based on Guide for Care and Use of Labora-
tory Animals of National Institutes of Health and approved by
Institutional Animal Care and Use Committee of Jiangsu Province Acad-
emy of Traditional Chinese Medicine (SYXK(SU) 2016-0017). PC9 and
H1975 xenograft tumors were established by subcutaneously injecting
each mouse in the right flank with 4 × 106 cells suspended in PBS
mixed 1:1 with Corning Matrigel (Corning, Cat. No.356237). Tumor
size was measured in two orthogonal directions using calipers every
two days and weights were determined twice weekly. When
established tumors become palpable (~100 mm3), mice were
randomised into vehicle group and treated groups with osimertinib
alone, TPX-0005 alone, osimertinib plus TPX-0005. Osimertinib was
suspended in 0.5% [weight/volume (w/v)]methylcellulose and adminis-
tered once daily by oral gavage (1 mg/kg osimertinib for the PC9 andositiveNSCLCpatients. A.Median progression-free survivalwas 23.4months (95% CI, 9.4 to
with high AXLmRNA expression; p b 0.001 (Cohort 1). B. Median progression-free survival
I, 4.5 to 14.2) for the 24 patientswith highCDCP1mRNAexpression; p=0.0179 (Cohort 1).
als. D. Combined AXL and CDCP1mRNA expression higher than themedian denotes a high-
inedAXL or CDCP1mRNAexpression lower than themedian denotes a low-risk groupwith
. E.Median progression-free survivalwas 16.7 (95%CI, 11.1 to 22.0) for the 32patientswith
0.0025 (Cohort 2). F. Median progression-free survival was 16.7 months (95% CI, 11.0 to
nts with high CDCP1mRNA expression; p= 0.0062 (Cohort 2). G. Univariate analysis was
CDCP1mRNA expression higher than themedian denotes a high-risk groupwith a median
A expression lower than themedian denotes a low-risk groupwith amedian progression-
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Fig. 3. Innate resistance to osimertinib therapy in a patient with high expression of AXL and CDCP1. Panel A shows the positron emission tomography-computed tomography (PET-CT)
image of the patient at the time of diagnosis. Panel B shows the treatments the patient received for metastatic EGFR-mutation-positive NSCLC as well as the duration of each treatment.
Panel C shows CT images of the patient's lung disease before she received osimertinib, during the time she had a response to osimertinib, when the disease subsequently relapsed at
4 months, and continue to progress after one cycle of chemotherapy. Panel D shows the results of the molecular analysis performed in the patient's baseline tissue biopsy.
118 N. Karachaliou et al. / EBioMedicine 29 (2018) 112–127H1975 model). TPX0005 was suspended in 0.5% (w/v) methylcellulose
and administered once daily by oral gavage (30 mg/kg for the PC9 and
H1975 model). Mice in the untreated group were given the same vol-
umes of 0.5% (w/v) methylcellulose by oral gavage. The tumor volume
(mm3) was estimated using the equation length × (width)2 × 0.5.
2.12. Statistical Analysis
The primary endpoint of the study was to examine the potential ef-
fects of gene messenger RNA (mRNA) expression levels on survival.
Progression-free survival and overall survival were estimated by means
of the Kaplan–Meier method and compared with a nonparametric log-Fig. 2.Overall survival by the expression of biomarkers in 2 cohorts of EGFR-mutation-positive N
patients with low AXL and 19.2months (95% CI, 10.2 to 34.5) for the 21 patients with high AXLm
CI, 16.8 to 44.3) for the 24 patients with low CDCP1 and 19.1 months (95% CI, 8.6 to 40.7) for
analysis was performed in Cohort 1. The bars correspond to 95% confidence intervals. D. Comb
with a median overall survival of 18.2 months (95%CI, 3.2 to 19.2) and combined AXL or CDCP1
survival of 33.0 months (95% CI, 21.6 to 36.7); p=0.0031 (Cohort 1). E. Median overall surviva
(95% CI, 15.4 to 26.2) for the 21 patients with high AXLmRNA expression; p=0.0011 (Cohort 2
low CDCP1 and 22.8months (95%CI, 13.2 to 27.8) for the 19 patientswith high CDCP1mRNA exp
correspond to 95% confidence intervals. H. Combined AXL and CDCP1mRNA expression higher
(95%CI, 10.3 to 22.9) and combinedAXL orCDCP1mRNAexpression lower than themedian den
b 0.001 (Cohort 2).rank test. In addition to analyzing gene expression as a continuous vari-
able, expression levels were divided into two groups according to the
median relative expression. A multivariate Cox proportional hazard
model was applied with potential risk factors as covariates, obtaining
Hazard Ratios (HR) and their 95% confidence intervals (CI). Each analysis
was performed with the use of a two-sided 5% significance level and a
95%CI. Association between biomarkers was assessed using Spearman
correlation analysis. The statistical analyses were performed using SAS
version 9.4. Forest plots for subgroup analysis were generated using
GraphPad Prism 7.0. The preclinical data were analyzed with GraphPad
Prism statistical software using one-way or two-way ANOVA with ad
hoc Bonferroni post-test (for comparison of treatment effects).SCLC patients. A.Median overall survival was 40.7months (95% CI, 17.6 to 64.1) for the 21
RNA expression; p=0.0097 (Cohort 1). B. Median overall survival was 34.9 months (95%
the 24 patients with high CDCP1mRNA expression; p= 0.0300 (Cohort 1). C. Univariate
ined AXL and CDCP1mRNA expression higher than the median denotes a high-risk group
mRNA expression lower than themedian denotes a low-risk groupwith a median overall
l was 28.7 months (95% CI, 25.1 to 35.1) for the 32 patients with low AXL and 20.8 months
). F.Median overall survival was 28.7months (95% CI, 25.1 to 34.9) for the 34 patients with
ression; p=0.0056 (Cohort 2). G. Univariate analysiswas performed in Cohort 2. The bars
than the median denotes a high-risk group with a median overall survival of 19.2 months
otes a low-risk groupwith amedian overall survival of 27.8months (95%CI, 25.1 to 34.2); p
BA
Fig. 4.Quantitative RT-PCR analysis and phospho- RTK and non-RTK arrays in EGFR-mutation-positive NSCLC cell lines. Effects of genetic and pharmacologic inhibition of STAT3, YAP1 and SFKs
in PC9 andH1975 cells treatedwith anEGFRTKI A. Expressionof various genes in EGFR-mutation-positiveNSCLC cell lines.Heatmapdepicts genemRNAexpression (columns) in different EGFR-
mutation-positive NSCLC cell lines (rows) compared to the averagemRNA expression of each gene in all cell lines. B. Phospho-RTK profile in PC9 and H1975 cells obtained by human phospho-
kinase array. Each membrane contains kinase specific and positive control antibodies spotted in duplicate. Template tables show the location of tyrosine kinase antibody spotted onto human
phospho-RTK array. C. Phospho-kinase array profile in PC9 and H1975 cells obtained by human phospho-kinase array. Eachmembrane contains kinase specific and positive control antibodies
spotted in duplicate. Template tables show the location of tyrosine kinase antibody spotted onto human phospho-kinase array. D. PC9 cells were transiently transfected with STAT3, Src, YAP1,
YES, LYN or control siRNA (15 pmol/well). 24 h later cells were treated with serial dilutions of gefitinib. Cell viability was assessed by MTT assay after 72 h of treatment. Plots shown are rep-
resentative of three independent experiments. E. Effects of negative control siRNA or STAT3, YAP1, SRC, YES and LYN siRNA on STAT3, YAP1, SRC, YES and LYNmRNA expression after 24 h of trans-
fection. The control condition is set at 1 (arbitrary units). F. PC9 and H1975 cells were treated with serial dilutions of gefitinib or osimertinib, and TPX-0005 alone and with their double
combinations for 72 h. The cell viability was measured by MTT and the synergy between the drugs was determined using the Chou and Talalay method (Chou and Talalay plot or Fraction af-
fected [Fa] plot). Thedottedhorizontal line at 1 indicates the line of additive effect. Fa indicates the fractional inhibition for eachCoI. The results represent themeans of at least three independent
experiments. Data are presented as themeans± standard deviation. G. PC9 and H1975 cells grown in six-well plates (1000 cells/well) for 24 h and then left untreated or treatedwith gefitinib
(0.05 μM), osimertinib (0.02 μM), TPX-0005 (1 μM) alone andwith their double combinations. After 72 h,mediawas replacedwith freshmediawithout drugs. After sevenmore days cellswere
washed and stainedwith crystal violet and then photographed. The crystal violet was extracted and assayed by spectrophotometry. Data aremeans± standard deviation of three independent
experiments. One-way ANOVA test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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3.1. Co-expression of RTKs and Non-RTKs and Clinical Outcome to EGFR
Inhibition
Extending our previous work (Chaib et al., 2017), we re-analyzed
the baseline tissues of 64 EGFR-mutation-positive patients treated
with an EGFR TKI (Cohort 1) for AXL, CDCP1 and other RTK and non-
RTK mRNA expression. Gene expression levels were dichotomized at
the median (Supplementary Table 2). The Spearman correlation coeffi-
cients among the biomarkers explored are presented in Supplementary
Fig. 1. With a median follow-up of 26.7 months, median progression-
free survival was 14.1 (95%CI, 5.4 to 15.8) and 23.4 months (95%CI, 9.4
to 30.2) for patients with high and low AXL mRNA, respectively (p b0.001). Median progression-free survival was 9.1 (95%CI, 4.5 to 14.2)
and 20.2 months (95%CI, 8.5 to 30.2) for patients with high and low
CDCP1mRNA, respectively (p=0.0179) (Fig. 1A–C). 27% of the patients
co-expressed high AXL and CDCP1 mRNA. Significant differences were
observed in median overall survival according to AXL and CDCP1
mRNA expression (Fig. 2A–C). A multivariate Cox model suggested an
independent association of AXL and CDCP1 mRNA expression and
progression-free survival (hazard ratio [HR] for disease progression or
death, 1.72; 95%CI, 1.50 to 2.94; p = 0.0461 and 1.79; 95%CI, 1.78 to
3.14; p = 0.0407) and CDCP1 mRNA expression and overall survival
(HR for death, 2.23; 95%CI, 1.14 to 4.36; p =0.0192). In a two-gene
model, patients were divided into two groups: a high-risk group with
high both AXL and CDCP1 expression and a low-risk group with at
least one of the two genes low. The model yielded a strong association
FG
Fig. 4 (continued).
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Table 3
IC50 values and combination indexes of first-, second- and third-generation EGFR inhibitors in combination with TPX-0005 tested in EGFR-mutation-positive cell lines.
IC50 (μM) Combination Index
Gefitinib Afatinib Dacomitinib Osimertinib TPX-0005 Gefitinib + TPX-0005 Afatinib + TPX-0005 Dacomitinib + TPX-0005 Osimertinib + TPX-0005
PC9 0.05 b0.01 b0.01 0.02 1.00 0.68 synergism 0.80 synergism 0.57 synergism 0.60 synergism
H1975 10.00 0.04 0.15 0.02 1.00 0.84 additive 1.12 additive 0.84 additive 0.61 synergism
11–18 0.80 0.03 0.01 0.06 1.50 0.64 synergism 0.76 synergism 0.64 synergism 0.62 synergism
HCC4006 0.03 b0.01 b0.01 0.01 1.48 0.92 additive 0.93 additive 0.66 synergism 0.56 synergism
HCC827 0.02 b0.01 b0.01 0.01 0.43 0.75 synergism 0.73 synergism 0.63 synergism 0.75 synergism
122 N. Karachaliou et al. / EBioMedicine 29 (2018) 112–127between risk status and progression-free and overall survival (Figs. 1D
and 2D).
We next evaluated AXL and CDCP1mRNA expression in a second co-
hort of 53 EGFR-mutation-positive NSCLC patients (Cohort 2). The pa-
tients were classified into high and low group according to the pre-
specified in Cohort 1 median cut-off points for AXL (1.68) and CDCP1
(18.63) expression. 25% of the patients co-expressed high AXL and
CDCP1 mRNA. The median follow-up time was 26.2 months. We con-
firmed the inverse relationship of high AXL or CDCP1 expression with
progression-free and overall survival (Figs. 1E–G and 2E–G). The two-
genemodel defined according to AXL and CDCP1 expression of produced
similar results like in Cohort 1 (Figs. 1H and 2H). Althoughwe unable to
find significant correlations between biomarkers and response to EGFR
TKI in cohort 1, in Cohort 2, the objective response ratewas 72% (95% CI,
53 to 86) in the low AXLmRNA expression group and 28% (95% CI, 53 to
86) in the high AXLmRNA expression group (odds ratio 2.03; 95%CI 1.04
to 3.96; p =0.0346). We finally used R2 genomics visualization tool
(http://r2.amc.nl) (Santo et al., 2012) in a mixed lung tumor dataset
(Bild dataset), to confirm the inverse relation between AXL and CDCP1
mRNA levels and overall survival probability (Supplementary Fig. 2).
We report the case of a 78-year-old never smoker woman who was
found to have advanced poorly differentiated adenocarcinoma of the
lung in March, 2017 (Fig. 3). The diagnostic transbronchial tumor bi-
opsy specimen showed a point Leu858Arg exon 21 and an EGFR
Thr790Met point resistant mutation (allelic frequency of 0.009 ± 0%)
mutation (Rosell et al., 2017). Further molecular testing performed in
her tumor biopsy revealed high mRNA expression of AXL and CDCP1.
The patient was included in the AZENT (AZD9291 in EGFR-mutation-
positive NSCLC and concomitant Thr790Met pre-treatment) study
(NCT02841579) and started first-line treatment with osimertinib. First
restaging computed tomography (CT) after two months of treatment
showed partial response (Fig. 3). However, she did well only until two
months later when the second restaging CT showed worsening lung
tumor and pleural infiltration. Osimertinib was discontinued and che-
motherapy (carboplatin-pemetrexed) was administered. After a single
dose of chemotherapy, the disease rapidly worsened, with multi-
organ failure and finally death of the patient, only five months after
the initial diagnosis (Fig. 3). Our data indicate that, AXL and CDCP1
can affect clinical outcome to EGFR TKIs.
3.2. Transcriptional and Proteomic Profiling of EGFR-mutation-positive
NSCLC Cell Lines
We then profiled five EGFR-mutation-positive NSCLC cell lines for
the mRNA expression of RTK and non-RTK. PC9 cells showed high ex-
pression of most of the RTKs examined, including AXL and EGFR family
members. SFKs, FAK and YAP1, as well as CDCP1 and SHP2, were also
highly expressed in PC9 cells in comparison with the rest of the cell
lines. The H1975 cell line had low mRNA expression of AXL, MET, and
CDCP1, as well as SFKs, FAK SHP2 and YAP1, in comparison with the
rest of the cell lines (Fig. 4A). HCC827 cells had moderate expression
for most of the transcripts examined, with the exception ofMET, SHP2
and YAP1. Compared to the rest of the cell lines, HCC827 had the highest
mRNA expression of the receptor tyrosine kinase-like orphan receptor 1
(ROR1) (Karachaliou et al., 2014). HCC4006 had high expression of RTKsand lowexpression of non-RTKs, and 11–18 cells scored high expression
levels only for SFKs and FAK (Fig. 4A). Based on these results we decided
to use mainly the PC9 and H1975 cell lines for most of the rest of our
preclinical experiments. Considering that mRNA does not predict func-
tional activity, we then explored RTK and non-RTK activation using
phospho-RTK and phosphokinase arrays in PC9 and H1975 cells. Both
cell lines had several RTKs activated including AXL, MET, EGFR family
members and insulin growth factor 1 receptor. Mer, a member of the
TAM (Tyro3-AXL-Mer) family of RTKs (Linger et al., 2013), was also ac-
tivated in the H1975 cell line (Fig. 4B). PC9 cells had higher activation of
Src, YES and FAK in comparison with H1975 cells (Fig. 4C). Our findings
indicate that coexpression of multiple RTKs and non-RTKs may occur in
EGFR-mutation positive cells.
3.3. Correlation of mRNA with Protein Expression or Gene Amplification
An important issue that is commonly raised when mRNA analysis
data are reported is whether gene expression is correlated with protein
expression or activation. With our real-time PCR analysis, as shown in
Fig. 4A, high MET mRNA expression was detected in the HCC827 and
HCC4006 cell lines that are previously described to be MET phosphory-
lated (Kubo et al., 2009). We have also recently shown that AXLmRNA
expression is related to AXL protein expression, as defined by western
blotting and immunohistochemistry in EGFR-mutation-positive NSCLC
cell lines (Jacobsen et al., 2017). Finally, we have performed an explor-
atory analysis, where, in 14 tumor samples of the cohort 1 patients,
we investigated whether the immunohistochemistry expression of
both phosphorylated STAT3 at tyrosine 705 and phosphorylated
YAP1 at tyrosine 357 are correlated with the mRNA expression of
STAT3 and YAP1, respectively. For pSTAT3 immunohistochemistry anal-
ysis, any nuclear stainingwas considered positive (5 out of 14, 36%). The
non-parametric Wilcoxon test was used to compare the mRNA and im-
munohistochemistry results. No significant correlation was found be-
tween parameters (p =0.6892). Furthermore, a median two-sample
test was performed (p = 0.5909). For pYAP1 immunohistochemistry
analysis, the results were considered positive when nuclear staining
was observed with an histoscore ≥ 200 (5 out of 16, 31%). The non-
parametricWilcoxon testwas used to compare themRNAand immuno-
histochemistry results. Significant correlation was found between pa-
rameters (p = 0.034). Furthermore, a median two-sample test was
performed and a significant correlation was found (p= 0.0027).
3.4. Effect of TPX-0005 with EGFR TKIs in Cell Culture
We have reported the combinatorial efficacy of gefitinib or
osimertinib with TPCA-1 (STAT3 inhibitor) and AZD0530 (Src inhibitor)
in EGFR-mutation-positive cells and the inverse relation of STAT3 and
YAP1 mRNA expression with EGFR-TKI outcome (Chaib et al., 2017).
To get insight into how STAT3 and Src-YAP1 contribute to innate resis-
tance to EGFR TKI, STAT3, YAP1 and SFKs were knockdown by siRNA
and the half-maximal inhibitory concentration (IC50) of gefitinib and
osimertinib was calculated in PC9 and H1975 cells, respectively. Knock-
down of Src, YAP1, YES, LYN or STAT3 enhances sensitivity to EGFR TKI
(Fig. 4D, E and Supplementary Fig. 3). We next combined gefitinib or
osimertinib with the Src/FAK/JAK2 inhibitor TPX-0005 (Table 2 and
AB
C
D
PC9
H1975
123N. Karachaliou et al. / EBioMedicine 29 (2018) 112–127
EF
Fig. 5. Effects of the double combination of gefitinib or osimertinibwith TPX-0005 in EGFR-
mutation-positive NSCLC cells. A. Extracts from the PC9 cell line treated with gefitinib
(0.05 μM), TPX-0005 (1 μM), or the double combination for 24 h, were analyzed using
the indicated antibodies. Similar results were obtained in three independent experiments.
B. Representative immunofluorescence images showing total STAT3 and phospho-STAT3
expression and localization (green) in control, gefitinib, TPX-0005 and gefitinib plus
TPX-0005 treated PC9 cells. Cell nuclei were stained with DAPI (blue). Right: expression
levels and nuclear translocation of phospho-STAT3 were quantified using an
ImageStreamX imaging flow cytometer. C. Extracts from PC9, 11–18 and H1975 cell
lines treated with osimertinib (0.05, 0.8, and 0.02 μM respectively), TPX-0005 (1 μM), or
osimertinib combined with TPX-0005 for 24 h, were analyzed byWestern blotting using
the indicated antibodies. β-Actin was used as a loading control. Similar results were ob-
tained in three independent experiments. D. Heatmap depicts the mRNA expression of
genes (columns) in control cells and after indicated treatments (rows) compared to the
average mRNA expression of each gene in all cell lines. Gefitinib was used at 0.05 μM for
PC9, osimertinib was used at 0.02 μM for H1975 and TPX-0005 was used at 1 μM for
both cell lines. Quantitative RT-PCR time course experiments from two hours to seven
days identified five days as the optimal time-point to compare pathway signaling after
treatments (data not shown) and subsequent mRNA expression experiments are pre-
sented at this time point for consistency. Data were generated from a minimum of three
replicates. β-Actin was used to normalize gene expression. E. Extracts from the PC9 and
H1975 cell lines transfected with control siRNA or siRNA against STAT3, Src, YAP1, YES
and LYN, were analyzed using the indicated antibodies. Similar results were obtained in
three independent experiments. F. Extracts from the PC9 and H1975 cell lines treated
with dasatinib (50 and 100 μM respectively) or TPX-0005 (1 μM) for 24 h, were analyzed
byWestern blotting using the indicated antibodies. Similar results were obtained in three
independent experiments.
124 N. Karachaliou et al. / EBioMedicine 29 (2018) 112–127Supplementary Fig. 4), and examined cell viability. TPX-0005 was syn-
ergistic with gefitinib or osimertinib in PC9 and H1975 cells, respec-
tively (Fig. 4F and G). Gefitinib with TPX-0005 suppressed PC9 cells
migration (Supplementary Fig. 5). The combination of TPX-0005 was
consistently synergistic or additive with all EGFR TKIs tested (Table 3).
These results indicate that genetic or pharmacologic inhibition of SFKs
and/or STAT3 enhances the anti-tumor effect of EGFR TKIs.
3.5. Effect of TPX-0005 on STAT3, Src-YAP1 and RTK Signaling
We evaluated whether EGFR TKIs combined with TPX-0005 have
similar effect on EGFR downstream signal transduction pathways as
we have reported with the triple combination (Chaib et al., 2017). Gefi-
tinib suppressed EGFR, ERK1/2 and AKT phosphorylation but increased
or not ablated STAT3, paxillin and YAP1 phosphorylation in PC9 cells
(Fig. 5A). Gefitinib plus TPX-0005 abolished STAT3, paxillin and YAP1
phosphorylation and increased the expression of cleaved caspase-3.
We adopted immunofluorescence to track STAT3 activation state by
its intracellular localization. STAT3 was activated and translocated into
the nucleus with gefitinib but this did not occur with TPX-0005 and
the combination (Fig. 5B).
We then explored the effect of osimertinib with TPX-0005 on EGFR
downstream signal transduction pathways and RTKs in three EGFR-
mutation-positive NSCLC cell lines. Osimertinib not alone but combined
with TPX-0005 ablated STAT3, paxillin and YAP1 phosphorylation
(Fig. 5C). The osimertinib-induced Src and FAKphosphorylationwas ab-
rogated with TPX-0005 or the double combination. Similarly, CDCP1
phosphorylationwas diminishedwith TPX-0005 and the double combi-
nation (Fig. 5C). TPX-0005 had a minor effect on AXL total protein ex-
pression (Fig. 5C). TPX-0005 alone or combined with an EGFR TKI
abolished or attenuated themRNA expression of most of the transcripts
explored (Fig. 5D).We finally used siRNA knockdown to address the re-
lationship of Src-YAP1 and RTKs in EGFR-mutation-positive NSCLC
(Fig. 5E). Src, YES or LYN siRNA reduced YAP1 phosphorylation. AXL,
CDCP1 and MET phosphorylation were diminished when YAP1 or
SFKs were knocked-down, highlighting YAP1 and SFKs as regulatory
nodes for RTKs activation (Fig. 5E).
We also explored the combination of EGFR TKIs with the Src inhibi-
tor dasatinib. Dasatinib was highly synergistic with all EGFR TKIs in PC9
andH1975 cells (Supplementary Table 3). However in contrast with the
Src/FAK/JAK2 inhibitor TPX-0005, the Src inhibitor dasatinib induced
STAT3 and FAK phosphorylation (Fig. 5F).
The above data reconfirm our previous findings that EGFR inhibition
alone increases STAT3 and YAP1 expression and activation in EGFR-
mutation-positive cells. We also highlight the interplay between RTKs
and SFKs-YAP1. TPX-0005 suppressed the increased expression or acti-
vation of CDCP1 and AXL observed at baseline or upon treatment with
an EGFR TKI.
3.6. TPX-0005 and Osimertinib In Vivo
To determine the effect of EGFR TKI with TPX-0005 in vivo, nude
mice bearing PC9 or H1975 cells, grown subcutaneously as tumor xeno-
grafts, were randomised to receive vehicle, osimertinib and TPX-0005or
the agents in monotherapy. TPX-0005 significantly potentiated the ef-
fect of osimertinib in the PC9 and H1975models (Fig. 6). No substantial
toxicity was noted with the combination (Supplementary Fig. 6)
supporting the efficacy of osimertinib with TPX-0005 in inhibiting the
growth of EGFR-mutation-positive NSCLC.
4. Discussion
Previously, we found that gefitinib or osimertinib activates STAT3
and Src-YAP1 in EGFR-mutation-positive NSCLC cells (Chaib et al.,
2017). Here we find that the genetic or pharmacologic inhibition of
Src or SFKs diminishes YAP1, AXL and CDCP1 phosphorylation or
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Fig. 6. Effect of TPX-0005 and osimertinib in vivo. A.Mice with established PC9 tumors were treatedwith vehicle control, TPX-0005 (30mg/kg), osimertinib (1mg/kg) and TPX-0005 plus
osimertinib. Each point represents the mean ± standard deviation of the tumor volume (n= 6 per group). Statistically significant differences on day 21 are shown for osimertinib plus
TPX-0005 versus osimertinib alone (*p b 0.01). Statistically significant differences on day 21 are shown osimertinib plus TPX-0005 versus TPX-0005 alone (§p b 0.01). B. After 21 days, the
mice were killed and the tumors were removed and weighed. Tumor weights were individually plotted, and comparisons between of TPX-0005 plus osimertinib group and single drug
treatment groupswere analyzed by Student's t-test. The tumorweight obtainedwith of TPX-0005plus osimertinib in the PC9 xenograftmodelwas statistically significantly different com-
pared with osimertinib alone (*p b 0.05) and/or TPX-0005 alone (§p b 0.05). C. Representative PC9 tumors surgically removed. D. Mice with established H1975 tumors were treatedwith
vehicle control, TPX-0005 (30 mg/kg), osimertinib (1 mg/kg) and TPX-0005 plus osimertinib. Each point represents the mean ± standard deviation of the tumor volume (n = 6 per
group). Statistically significant differences on day 21 are shown for osimertinib plus TPX-0005 versus osimertinib alone (*p b 0.01). Statistically significant differences on day 21 are
shownosimertinib plus TPX-0005 versus TPX-0005 alone (§p b 0.001). E. After 21 days, themicewere killed and the tumorswere removed andweighed. Tumorweightswere individually
plotted, and comparisons between of TPX-0005 plus osimertinib group and single drug treatment groupswere analyzed by Student's t-test. The tumorweight obtained with of TPX-0005
plus osimertinib in the H1975 xenograft model was statistically significantly different compared with osimertinib alone (*p b 0.05) and/or TPX-0005 alone (§p b 0.00001). F. Represen-
tative H1975 tumors surgically removed. The two-sided Student's t-test was used for the statistical analysis.
125N. Karachaliou et al. / EBioMedicine 29 (2018) 112–127expression. In two cohorts of EGFR-mutation-positive NSCLC patients
treated with EGFR TKI, we show that a risk-model combining AXL and
CDCP1 mRNA expression was strongly associated with progression-
free survival with hazard ratios of 2.95 and 2.19 and overall survival
with hazard ratios of 3.56 and 2.96 between high-risk and low-risk
group.
In accordance with earlier findings (Yoshida et al., 2014), we show
that EGFR-mutation-positive NSCLC cells co-express more than just
EGFR RTKs. Non-RTKs, especially, Src, YES and FAK, are also expressed
and activated. Combined EGFR TKI with TPX-0005 is more effective
than EGFR TKI alone both in culture and in vivo. At the time of our
work, it was reported that the AKT and the mitogen-activated protein
kinase (MAPK) pathways remain active, even in the presence of
osimertinib (Ichihara et al., 2017). EGFR, SFK and FAK concomitant inhi-
bition enhances osimertinib activity and suppresses resistance (Ichihara
et al., 2017). Although co-targeting EGFR andMEK (known as mitogen-
activated protein kinase kinase 1, or MAP2K1) (Tricker et al., 2015) or,
from our experience, AKT (Jacobsen et al., 2017), causes growth inhibi-
tion in EGFRTKI resistantNSCLCmodels, the combination of osimertinib
with dasatinib was superior to the combination of osimertinib with
MEK or phosphoinositide 3-kinase (PI3K) inhibitor inhibitors (Ichihara
et al., 2017). In summary, three studies show that SFK and FAK contrib-
ute to EGFR TKI resistance (Yoshida et al., 2014; Ichihara et al., 2017;
Murakami et al., 2017).
Tyrosine kinase inhibitors do not induce the activation of new RTKs,
rather, only increase the phosphorylation of existing RTKs to compen-
sate the reduced phosphorylation of ERK and AKT. A combination of
TKIs could completely inactivate all the RTKs and their downstreamsignaling molecules (Sun et al., 2016). Paradoxically, inhibition of AXL
or MET led to greater Src-induced AXL and MET phosphorylation in
breast and lung cancer cell lines (Baumann et al., 2017). CDCP1 overex-
pression triggered a cascade of tyrosine phosphorylation events, leading
to the activation of signaling networks, including SFKs, to promote
tumor cell growth and survival (Leroy et al., 2015). Through the combi-
nation of genomic, biological, in vivo models and clinical cohorts of pa-
tients, ourfindings lead to themodel in Fig. 7. Our data indicate that Src-
YAP1 signaling leads to further activation of AXL, CDCP1 and MET
(Fig. 5E). By targeting SFK and FAK, we can obviate the need to inhibit
thedominant RTKs that can be activatedwith theparadoxical detrimen-
tal effect of causingmore activation (Baumann et al., 2017). The combi-
nation of a TKI plus SFK and FAK inhibitor has been proposed (Yoshida
et al., 2014; Ichihara et al., 2017; Murakami et al., 2017). However, in
our work, dasatinib induced STAT3 and FAK phosphorylation (Fig. 5F).
Erlotinib plus dasatinib was not effective in a clinical trial in EGFR-
mutation-positive NSCLC patients with acquired resistance to erlotinib
or gefitinib (Johnson et al., 2011). Clinical trials with EGFR TKI plus
SFK and FAK inhibitors, such as the Src/FAK/JAK2 inhibitor TPX-0005,
deserve to be carried out.
A trial is foreseen with osimertinib plus TPX-0005 and, according to
our knowledge, TPX-0005 is the only compound that inhibits Src, FAK
and JAK2 at a similar affinity level. Finally, we advocate customizing
the therapy of EGFR-mutation-positive NSCLC patients and the use of a
tool kit to optimize EGFR mutational screening by incorporating
CDCP1 and AXLmRNA assessment.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2018.02.001.
Fig. 7.Our Signal transduction pathwaymodel EGFR activatingmutations located in the tyrosine kinase domains andmainly in the formof a base-pair deletion at exon 19 (ΔE746_A750) or
a point mutation at exon 21 (Leu858Arg) enhance cell growth and invasion via tyrosine phosphorylation and lead to the activation of mitogen-activated protein kinase (MAPK), signal
transducer and activator of transcription 3 (STAT3) and AKT pathways. SHP2, a widely expressed cytoplasmic tyrosine phosphatase with two src homology (SH)2 domains plays an
essential role in most receptor-tyrosine kinase (RTK) signaling pathways. SHP2 function is required for MAPK pathway and activation of its downstream transcriptional targets. When
phosphorylated on tyrosine 542, SHP2 increases the half-life of activated Ras (GTP-Ras) in the cell by interfering with the process of Ras inactivation catalyzed by Ras GTPase-
activating protein (RasGAP). Raf activates MAPK/ERK Kinase 1 (MEK1) and MEK2. Extracellular signal-regulated kinase (ERK1 and ERK2) is activated upon phosphorylation by MEK1/
2. Dual threonine 202 and tyrosine 204 residue phosphorylation activate ERK1. AKT is the major downstream target of phosphatidylinositol 3-kinase (PI3K), which is activated by
EGFR. When PI3K is activated induces the recruitment of AKT to the cell membrane. The recruitment of AKT to the cell membrane drives a conformational change in the protein. This
enables AKT phosphorylation on serine 473, which is required for full activation. Following activation, AKT translocates to the cytoplasm and nucleus, and phosphorylates various
downstream substrates including mammalian target of rapamycin (mTOR). mTOR regulates the serine/threonine kinase, p70S6K, whose function regulates protein synthesis. STAT3
can be activated not only by growth factor receptors, like EGFR, but also by interleukins, like IL-6. The transforming growth factor-beta (TGF-β) drives the expression of IL-6. IL-6 is a
glycoprotein which first binds to a-chain (IL-6R) and then recruits the b-chain (gp130) of the receptor. Subsequently, the IL-6/IL-6R complex initiates homo-dimerization of gp130,
activates a cytoplasmic tyrosine kinase bound to gp130 and triggers signaling cascades through janus-like kinase (JAK) and Src kinase. JAK2 mediates STAT3 phosphorylation and
activation. The major phosphorylation site in STAT3 is tyrosine at position 705. When activated, STAT3 undergoes phosphorylation-induced homo-dimerization, leading to nuclear
translocation, DNA binding and gene transcription. Independently of STAT3, gp130 activates the Yes-Associated Protein (YAP1) oncoprotein through direct association with the Src
family kinase (SFK) Yes. SHP2 activates several SFKs, including Src as top hit. Upon Src activation, several downstream Src binding partners are targeted for phosphorylation, including
paxillin on tyrosine 118. YAP1 is normally kept inactive in the cytoplasm through serine phosphorylation by the Hippo effector large tumor suppressor kinases (LATS). One Hippo
independent mechanism implicated in cancer involves phosphorylation of YAP1 on tyrosine 357 by Yes1. As a transcriptional co-activator, YAP1 has been reported to bind several
DNA-binding transcription factors. Among the reported YAP1 partners, the TEA domain (TEAD) transcription factor is well characterized. Connective tissue growth factor (CTGF) is a
prototypical target of the YAP1-TEAD complex and a commonly used marker of YAP1 activation. Several RTKs or their ligands have been described as mediators of YAP1-dependent
oncogenic activities. The tumor microenvironment-derived ligand hepatocyte growth factor (HGF) induces inter-receptor cross talk of MET with erythropoietin-producing
hepatocellular receptor A2 (EphA2), the complement C1r/C1s, Uegf, Bmp1 (CUB) domain-containing protein-1 (CDCP1) or AXL. This provides an alternative signaling mechanism for
EGFR, thereby circumventing TKI resistance. SHP2 modulates RTK signals at the level of the MAPK pathway. EGFR-TKI combined with the Src/FAK/JAK2 inhibitor TPX-0005 may more
efficiently block the EGFR downstream signaling pathways than EGFR-TKI alone.
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